Fibroblast growth factor 23 and Klotho protein: assessment of the role in the development of secondary hyperparathyroidism in patients with various stages of chronic kidney disease

Main Article Content

N.V. Karlovich
T.V. Mokhort


Background. Secondary hyperparathyroidism (SHPT) is universal complication of chronic kidney disease (CKD), the likelihood of which increases as renal function decreases. Currently, SHPT is considered in the context of mineral and bone disorders associated with CKD. Mineral and bone disorders associated with CKD include, in addition to SHPT, disorders of calcium-phosphorus metabolism, bone pathology and metastatic calcification, which determine poor outcomes of the disease. The purpose of the study was to evaluate the serum concentrations of fibroblast growth factor (FGF) 23 and Klotho protein in patients with various stages of CKD and their relationship with SHPT, vitamin D levels, and calcium-phosphorus metabolism in patients with varying degrees of decreased renal function. Materials and methods. Serum concentrations of FGF 23, Klotho protein, parathyroid hormone (PTH), 25(OH)D, calcium and phosphorus were evaluated in 229 patients with various stages of chronic kidney disease and in 40 people without signs of CKD. Results. It has been shown that individuals with CKD are characterized by overproduction of humoral phosphatonin FGF 23 and Klotho deficiency, which increase as renal failure worsens. A significant relationship was established between FGF 23 and the levels of PTH and blood phosphorus; Klotho protein — with the patient’s age and serum vitamin D. An early marker of disorders in the FGF 23-Klotho system is a decrease in the Klotho protein concentration, which occurs in the early stages of CKD and is aggravated with the progression of renal failure. A statistically significant overproduction of FGF 23 associated with secondary hyperparathyroidism was registered in patients with glomerular filtration rate less than 35 ml/min/1.73 m2. Conclusions. An early marker of disorders in the FGF 23-Klotho system is a decrease in the concentration of the Klotho protein, which occurs in the early stages of CKD and is aggravated with the progression of renal fai-
lure. The relationship between Klotho deficiency and the formation of SHPT has not been found. As kidney function decreases, excess production of PTH and FGF 23 appears and increases, hyperphosphatemia progresses. This proves the pathogenetic relationship between the formation of SHPT and the overproduction of humoral phosphatonin FGF 23, since it is this glomerular filtration rate that determines the growth of PTH above the upper limit of the general population reference interval.

Article Details

How to Cite
Karlovich, N., and T. Mokhort. “Fibroblast Growth Factor 23 and Klotho Protein: Assessment of the Role in the Development of Secondary Hyperparathyroidism in Patients With Various Stages of Chronic Kidney Disease”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 5, Oct. 2021, pp. 385-92, doi:10.22141/2224-0721.17.5.2021.241516.
Original Researches


Mizobuchi M, Ogata H, Koiwa F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment. Ther Apher Dial. 2019 Aug;23(4):309-318. doi:10.1111/1744-9987.12772.

Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Fam Med. 2009 Sep-Oct;22(5):574-81. doi:10.3122/jabfm.2009.05.090026.

Karlovych NV, Mokhort TV. Secondary hyperparathyroidism and chronic kidney disease. Minsk; 2021. 177 p. (in Russian).

Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66. doi:10.1002/wdev.176.

Haussler MR, Whitfield GK, Kaneko I, et al. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 2012 Mar;13(1):57-69. doi:10.1007/s11154-011-9199-8.

Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 Jun;79(12):1370-8. doi:10.1038/ki.2011.47.

Kovesdy CP, Quarles LD. FGF23 from bench to bedside. Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1168-74. doi:10.1152/ajprenal.00606.2015.

Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010 Sep;21(9):1427-35. doi:10.1681/ASN.2009121293.

Alvarez-Cienfuegos A, Cantero-Nieto L, Garcia-Gomez JA, Robledo G, González-Gay MA, Ortego-Centeno N. FGF23-Klotho axis in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020 Jan-Feb;38(1):50-57.

Ribeiro AL, Mendes F, Carias E, et al. FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease. J Diabetes Complications. 2020 Jan;34(1):107476. doi:10.1016/j.jdiacomp.2019.107476.

Canney M, Djurdjev O, Tang M, et al. GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. Am J Nephrol. 2019;50(2):105-114. doi:10.1159/000501189.

Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi:10.1210/jc.2011-0385.

Obi Y, Hamano T, Isaka Y. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers. 2015;2015:868961. doi:10.1155/2015/868961.

Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001 Jan;37(1 Suppl 2):S66-70. doi:10.1053/ajkd.2001.20748.

Chadban SJ, Ahn C, Axelrod DA, et al. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr;104(4):708-714. doi:10.1097/TP.0000000000003137.

Karlovich NV, Spiridonova OS, Sazonova EG, Mokhort TV. Determination of the parathyroid hormone reference interval in patients with different stages of the chronic kidney disease. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(2):186-195. doi:10.29235/1814-6023-2021-18-2-186-195. (in Russian).

Pankiv VI, Yuzvenko TYu, Pankiv IV. Type 2 diabetes mellitus and subclinical hypothyroidism: focusing on the role of cholecalciferol. Problems of Endocrine Pathology. 2019;68(2):46-51. doi:10.21856/j-PEP.2019.2.07.

Cherenko SM, Dinets A, Bandura GV, Sheptuha SA, Larin OS. Multiglandular Parathyroid Gland Disease: An Incidental Discovery In Normocalcemic Patients During Thyroid Surgery. Acta Endocrinol (Buchar). 2017 Jul-Sep;13(3):349-355. doi:10.4183/aeb.2017.349.

Pankiv IV. Vitamin D: new aspects of application, effective doses. The current state of the problem. Mìžnarodnij endokrinologìčnij žurnal. 2021;17(1):50-54. doi:10.22141/2224-0721.17.1.2021.226430. (in Ukrainian).

Most read articles by the same author(s)